Background
Introduction
Essential oils and their components extracted from vegetable materials have been found to exhibit anti-microbial, anti-viral, anti-fungal, anti-oxidant, anti-inflammatory and anti-cancer activities [1] [2] [3] .
Monoterpenes are major plant-derived secondary metabolites widely found in natural products, including fruits, vegetables and herbs and known to be associated with the plant defense mechanisms. The monoterpenes consist of two isoprene units, and are found in large amounts in essential oils [4, 5] . In addition, many monoterpenes have been proposed to exert potent anticancer activity. Some of them reportedly displayed promising results in the prevention and treatment of different types of leukemia and cancers, such as breast, skin, pancreatic and colon cancers in rodents [6] . Notably, several of these compounds, among them Perillyl alcohol and limonene, are being testing in ongoing human studies [7] [8] [9] .
Terpinen-4-ol, one of the primary active ingredients of the tea tree oil, consists of a mixture of more than 100 different compounds, and is found in a variety of aromatic plants (oranges, mandarins, origanum, New Zealand lemonwood tree, Japanese cedarand black pepper) [10] . Terpinen-4-ol is a potent bactericidal agent [11] that possess antifungal properties [12] . Of particular interest is its in vitro activity against Staphylococcus aureus and C. albicans [13, 14] . It was shown that combining this natural substance and conventional drugs may help treat resistant yeast and bacterial infections.
Several recent reports have suggested that terpinen-4-ol induces antitumor effects by selectively causing necrotic cell death and cell-cycle arrest in melanoma cell lines, or by triggering caspase-dependent apoptosis in human melanoma cells, particularly in drug (Adriamycin) resistant cells [15, 16] . Moreover, terpinen-4-ol was shown to elicit a dose-dependent cytotoxic response on human non-small cell lung cancer cells, presumably through the involvement of the mitochondrial apoptotic pathway [17] .
CD24 is a small, heavily glycosylated mucin-like cell surface protein anchored to the membrane via glycosyl phosphatidylinositol (GPI) [18] . CD24 is known to be overexpressed in various human malignancies, both solid and hematological [19] , and is usually tied with a more aggressive course of the disease [18, 20, 21] . We have shown that anti-CD24-based cancer immunotherapy has potential clinical application in solid tumors [21] [22] [23] . Therefore, the combination of terpinen-4-ol together with anti-CD24 therapy was evaluated in this work.
In this study, we aimed to show the anticancer effects of terpinen-4-ol in various types of cancer cells in vitro and in vivo. It is also shown that Terpinen-4-ol can restore the potency of cetuximab in tumors with a mutant RAS.
Materials and Methods Materials
All reagents were purchased from Sigma, Israel unless otherwise stated. Cell culture media and additives were obtained from Beit-Haemek, Israel. Annexin V and propidium iodide were purchased from Biotium.
The following materials were tested:
1. Terpinene-4-ol 2. Mixture 1 = γ-terpinene, α-terpinene, 1,8-cineole, p-cymene, terpinene-4-ol
The ratio of each compound is described in Table 1 .
The following chemotherapy drugs and antibodies were tested:
1. ElOXATIN 1 (Oxaliplatin) at a concentrations ranging between 0.2-0.5 μM.
5-FU (
3. GEMZAR (Gemcitabine)-0.1-1 μM 4. Tarceva (0.05-0.1 μM).
5. Erbitux (Cetuximab) at a concentration range of 1 μM.
6. Humanized anti-CD24 mAb (humanized IgG1 antibody that binds to the cell surface CD24 protein) at concentrations of 75-150 μg/ml.
Cell lines
Human CRC (HT29, HCT116, COLO320), gastric carcinoma (AGS), pancreas (COLO357, Panc-1, MIA-PACA) cells lines were grown in high-glucose Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% heat-inactivated (HI) fetal bovine serum (FBS), 1% glutamine and streptomycin/penicillin. An androgen-independent prostate (DU145, CL-1), and colorectal DLD1 cancer cells were grown in RPMI-1640 medium supplemented with 5% HI-FBS.
MTT cell viability assay
Cells were seeded in 96-well plates (1x10 4 cells/well) in complete medium. On the following day, different concentrations of the above-described agents were added to the cells in triplicates.
At 72 h later, the medium was replaced by fresh media (100 μl per well) containing 1 mg/ml 
Transfection and luciferase assay
Transfections were performed using jetPEI™ (Polyplus-transfection Inc, NY, USA) according to the manufacturer's instructions. 5 x 10 5 HCT116 cells were seeded in 6-well plates for Luc assays. The next day, when the cells were about 50% confluent, co-transfection with 3 μg of PY4-SV40-LUC vector plus 0.3 ng of pRL-CMV (Promega) was performed. 24h after the transfection medium was replaced and the cells were exposed to cetuximab, different concentration of terpinen-4-ol or left untreated. Luc assay was performed 48 h post after the treatment. Briefly, cells were washed once with PBS and then lyzed in 250~μl of lysis buffer for 5 min at room temperature. The lysates were centrifuged at 14,000 rpm for 5 min, and 20 μl of each lysate were used to measure Luc reporter gene expression. The Luc activity was normalized to Renilla Luc activity from a parallel co-transfection of pRL-CMVDual Luc system, Promega). , the mice were randomly divided into groups and the treatment was started (intraperitoneal and/or intratumoral injections). The animals were treated twice a week for 3 weeks. They were weighed and tumor volume was measured with a caliper and plotted every 3 days starting from the onset the treatment. Tumor volume was calculated as 4/3πÁaÁb 2 . At the end of the experiment, the mice were anesthetized and sacrificed by cervical dislocation and the tumors were excised.
Detection of cell death

Statistics
Data from the in vitro studies are presented as mean±SD of sets of data as determined in triplicates. Statistical significance between treatments was determined by Student's t-test, and P values < .05 were considered significant. In the in vivo studies, the tumor-bearing mice were randomized into 5 treatment groups and the tumor volumes were periodically monitored and calculated as 4/3πÁaÁb 2 . Significant differences between groups and at different time points were determined by Student's t-test.
Study approval
The study was approved by the institutional committee for animal welfare at Tel-Aviv Sourasky Medical Center.
Results
Identification of terpinen-4-ol as the effective ingredient
Two mixtures with different monoterpens composition were tested (Table 1) . Mixture 1 was significantly more effective and toxic than mixture 2 (P<0.005). The main difference between the two was terpinen-4-ol. The results (Fig 1A) indicated for significant differences in cell survival between the mixtures, allowing us to identify terpinen-4-ol and its contribution to the cytotoxic effect.
No effect of DMSO on the activity of terpinen-4-ol
One of the obstacles that is encountered when using cytotoxic compounds as therapeutic agents is their low solubility in pharmaceutically solutions and their low ability to penetrate into cells. To that extent, we examined whether terpinen-4-ol will be active in the absence of dimethyl sulfoxide (DMSO). DMSO was used to dissolve terpinen-4-ol and its effect was evaluated. It emerged that the cytotoxic activity of terpinen-4-ol was not hampered by adding Fig 1. A. Identification and isolation of terpinen-4-ol. Two mixtures (their composition is described in Table 1 ) of monoterpens were tested on colorectal (HCT116, DLD1, COLO320), gastric (AGS), pancreatic (PANC-1, COLO357, MIA-PACA) and prostate (CL-1, DU145) cancer cell lines. 1x10 4 cells were seeded in 96-well plates in complete medium. 0.05% of the mixtures were added to the cells on the next day. Cell survival was evaluated by enzymatic MTT assay72 h after the treatment. Each bar represents the mean ±SD of a set of data determined in triplicates. *P < .05, **P < .005. B. Terpinen-4-ol activity does not depend on the presence of DMSO. 1x10 4 CRC, gastric, pancreatic and prostate cancer cells were seeded in 96-well plates in complete medium.0.05% of terpinen-4-ol with or without 0.01% DMSO was added to the cells on the next day. Cell survival was evaluated by enzymatic MTT assay72 h after the treatment. Each bar represents the mean±SD of a set of data determined in triplicates. *P < .05, **P < .005. DMSO (Fig 1B) . Several concentrations of terpinen-4-ol (0.005%-0.1%) with and without DMSO were tested (data not shown) and the difference in the effect of DMSO was observed mainly at higher doses of terpinen-4-ol. DMSO seemed interfere or inhibit the biological effect of terpinen-4-ol, maybe by hindering the absorption of this biologically active molecule.
Terpinen-4-ol as an anti-cancer agent
Terpinen-4-ol inhibited the growth of colorectal (Fig 2A), pancreatic (Fig 2B), gastric (Fig 2C) and prostate (Fig 2D) cancers in a dose-dependent fashion [10% (in 0.005%)-90 (in 0.1%) growth inhibition)], as measured qualitatively by microscopic observations (data not shown) and quantitatively by the enzymatic MTT assay (Fig 2) .
Terpinen-4-ol induces apoptosis and not necrosis
Low concentrations of terpinen-4-ol (0.005-0.01%) inhibited HCT116 cell proliferation in a modest way (20-30%) as measured by the MTT viability assay. High concentrations (0.05-0.1%), induced massive cell death (75-90%). As can be seen in Fig 3, apoptosis is the cell death mechanism responsible for the cytotoxic effect induced by Terpinen-4-ol. Early apoptotic death was induced by low dose of terpinen-4-ol, whereas the percentages of late apoptosis increased at higher concentrations. No necrotic cells were observed.
Enhancement of terpinen-4-ol efficacy
Terpinen-4-ol was combined with different types of conventional chemotherapy, depending on the type of cancer being treated. For CRC therapy, terpinen-4-ol was combined with oxaliplatin ( Fig 4A) and 5-FU (Fig 4B) . An impressive synergistic growth inhibition effect was Terpinen-4-ol Treatment for CRC achieved (83% and 91%, for oxaliplatin and 5-FU, respectively) in the combined regimen as compared to each agent alone [12% (oxaliplatin), 25% (terpinen-4-ol), and 20% (5-FU)]. These results have achieved statistical significance, P<0.005. Similar results were obtained in pancreatic cancer cells (Fig 4C-4F) . Terpinen-4-ol impressively increased the efficacy of gemcitabine and that of Tarceva (60-85% cell death).
Enhanced cytotoxicity of terpinen-4-ol with biological agents
Combining terpinen-4-ol with either humanized anti-CD24 matured antibody (Arber's lab, Tel Aviv, Israel) or the chimeric anti EGFR antibody (Cetuximab, Merck Serono) resulted in a remarkable synergistic growth inhibition effect (85-90%, P<0.005) on human CRC (Fig 5A and 5B) and prostate cancer cells (Fig 5C and 5D ).
Terpinen-4-ol restores the sensitivity of K-ras mutant cancer cells to ceteximub
The DLD1 CRC cells carry a mutation in the KRAS oncogene. Therefore, they are resistant to anti-epidermal growth factor (EGFR) therapy. Combining terpinen-4-ol (0.01%) with cetuximab (1 μM) resulted in a rather impressive efficacy of a 85-90% growth inhibition. These results were confirmed in another KRAS mutated CRC cell line (HCT116) (Fig 5E) , with an 80% growth inhibition (P<0.005) for the combined therapy.
Decreased activity of K-ras signaling pathway with terpinen-4-ol
For that purpose we used the (Ets/Ap1) 4 RAS-responsive element (Py4) construct, which we had previously constructed [24] [25] [26] . The activity of the KRAS pathway was evaluated in mutated CRC cells (HCT116) (Fig 5F) . Transfection with Py4-SV40-Luc activity in the presence of terpinen-4-ol (0.005 and 0.01%) was 1.3 and 1.5 fold lower as compared to the activity in its absence (P<0.05)_. No effect was observed after exposure to cetuximab (1 μM).
Inhibition of subcutaneous DLD1 tumor growth in mice by terpinen-4-ol
Next, we tested the potential anti-tumor activity of terpinen-4-ol in vivo. Intratumoral injections (5 injections) of the compound (0.1% and 1%) were given twice weekly to nude mice (n = 6) bearing xenografts of CRC DLD1 cells. The treatment was started when tumors were 0.3-0.5 cm 3 . Significant inhibition of tumor development was observed; 40% and 70% reduction in tumor volume and about 25% and 50% reduction of tumor weight (Fig 6A) . These results were confirmed in another experiment (Fig 6B) . No significant adverse effects were observed (data not shown).
Combined growth inhibition of subcutaneous tumors in mice
When one of tumor's diameter reached the size of 0.5 mm intratumoral injections of terpinen-4-ol (0.1%) along with systemic (IP) administration of cetuximab (10 mg/kg) resulted in a significant decrease in tumor volume (62% ±2.5%, P<0.05) and weight (62.5% ±3%, P<0.05) (Fig 6C) Design of a more effective formulation of terpinen-4-ol
Two different formulations of terpinen-4-ol were evaluated in vivo, a nano and suspension formulations. The latter emerged as being more effective and safer (data not shown). Systemic administration of the suspension (1 and 4 mg) to mice bearing xenografts of CRC (HCT116) cells resulted in an impressive decrease in tumor volume (32%±1.1%, P<0.05 and 72%± 0.7%, P<0.005, respectively) and weight (26% ±1.19 and 70% ± 0.71%, P<0.005, respectively) in a dose-dependent manner (Fig 7) .
Discussion
The anticancer effects of terpinen-4-ol are impressive in various types of cancer cells both in vitro and in vivo.
Terpinen-4-ol is a major component of essential oil derived from several aromatic plants. It is used as an anti-inflammatory and antioxidant agent [27] [28] [29] . The contribution of terpinen-4-ol as an anti-cancer agent and the underlying signaling pathways of different types of cell death are unknown. Herein, it is shown that the mechanism of action of terpinen-4-ol is induction of apoptosis and not necrosis. It is also shown that terpinen-4-ol and various anticancer agents demonstrate a synergistic growth inhibitory effect by decreasing the survival of various cancer cell lines. Such combinations maybe expected to be more effective and less toxic since lower drug concentrations can be used for treating a wide range of cancers.
Of note, restoring sensitivity to anti-EGFR therapies (e.g. cetuximab), in CRC cases carrying the KRAS mutation, when given along with terpinen-4-ol has a merit clinical importance. It is demonstrated by measuring the activity of the ras responsive promoter before and after 6 HCT116 cells were seeded in 6-well plates in triplicates. The next day, co-transfection with PY4-SV40-LUC vector and pRL-CMV was performed. 24h after the transfection medium was replaced and the cells were exposed to cetuximab, different concentration of terpinen-4-ol or left untreated. Luc assay was performed 48 h post after the treatment. Each bar represents the mean±SD of a set of data determined in triplicates. *P < .05, **P < .05 doi:10.1371/journal.pone.0156540.g005
Terpinen-4-ol Treatment for CRC exposure to terpinen-4-ol. It is shown that the promoter activity was significantly reduced upon exposure to Terpenin-4-ol. This interesting and important observation needs to be confirmed in further laboratory studies before leading to any clinical use of terpinuin-4-ol.
Injection of terpinen-4-ol into the tumor remarkably inhibited tumor growth without any significant adverse effects. In search for more convenient routes of administration, two pharmaceutical formulations were prepared and tested for systemic administration, nano formulation and suspension. Nano formulations increased the surface area and therefore dramatically improved water solubility, bioavailability, effectiveness and efficiency. The suspension form was composed of small drops/molecules of the therapeutically active ingredient (the oil) in a suspension medium. Since the nanodrops were associated with serious toxicity (loss of body weight, mortality), the suspension approach that was devoid of any side effects was chosen for further exploration. The systemic administration of terpinen-4-ol by suspension was associated with a significant reduction in tumor size in the experimental nude mice.
In summary, the use of a combination of plant-derived anticancer substances and chemotherapeutic or biological agents for treating various types of cancer is promising, with a synergetic efficacy that allow a lower concentration of chemotherapy and biological agents that can not only increase efficacy but can minimize toxicity as well. Most importantly terpinen-4-ol major advantage is the capability to restore the sensitivity to EGFR antagonists in tumors with Ras mutations. Exponentially growing HCT116 cancer cells were harvested and resuspended at a final concentration of 5x10 6 cells per 0.1 ml PBS per injection. When the tumors were palpable, mice were randomly divided into 3groups and the treatment, consisting of intraperitoneal injections of terpinen-4-ol (1 and 4 mg/kg), was started. The mice were treated twice weekly. They were weighed and tumor volume was measured with a caliper every 3 days starting from the onset of treatment with terpinen-4-ol. The tumor volume vs. time of treatment was plotted. At the end of the experiment, the mice were anesthetized and sacrificed by cervical dislocation and the tumors were excised and measured for volume and weight. Each bar represents the mean±SD. *P < .05, **P < .005 doi:10.1371/journal.pone.0156540.g007
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